Cargando…

Systematic Review and Meta-Analysis of Randomized Controlled Trials of Fuke Qianjin Tablet

PURPOSE: The aim of the research was to evaluate the efficacy and safety associated with Fuke Qianjin tablet combined with conventional therapy in the treatment of pelvic inflammatory diseases and associated complications (endometritis) using a meta-analysis approach. Patients and Methods. We search...

Descripción completa

Detalles Bibliográficos
Autores principales: Jie, Pan, Kai-Ni, Zuo, Xiao-Mei, Wang, Meng-Pei, Zhang, Zhi-Heng, Wang, Hao-Xiang, Zhang, Wen-Tao, Zhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904366/
https://www.ncbi.nlm.nih.gov/pubmed/33680066
http://dx.doi.org/10.1155/2021/8861631
_version_ 1783654913439432704
author Jie, Pan
Kai-Ni, Zuo
Xiao-Mei, Wang
Meng-Pei, Zhang
Zhi-Heng, Wang
Hao-Xiang, Zhang
Wen-Tao, Zhu
author_facet Jie, Pan
Kai-Ni, Zuo
Xiao-Mei, Wang
Meng-Pei, Zhang
Zhi-Heng, Wang
Hao-Xiang, Zhang
Wen-Tao, Zhu
author_sort Jie, Pan
collection PubMed
description PURPOSE: The aim of the research was to evaluate the efficacy and safety associated with Fuke Qianjin tablet combined with conventional therapy in the treatment of pelvic inflammatory diseases and associated complications (endometritis) using a meta-analysis approach. Patients and Methods. We searched 8 electronic databases up to December 31, 2019, including PubMed, the Cochrane Library, Embase, Web of Science, CNKI, WanFang, VIP, and SinoMed. Eligible studies were clinical trials of Fuke Qianjin tablet combined with conventional therapy used in the treatment of acute pelvic inflammatory disease, chronic pelvic inflammatory disease, and endometritis. The meta-analysis was performed using STATA15 software. RESULTS: A total of 125 RCTs (n = 14,494) were shortlisted for the meta-analysis, which included 23 trials for acute pelvic inflammatory disease, 69 trials for chronic pelvic inflammatory disease, and 33 trials for endometritis. The overall analysis illustrated Fuke Qianjin tablet combined with conventional therapy was significantly more efficacious than conventional therapy alone across all types of antibiotics treatment for acute pelvic inflammatory disease (OR = 5.57, 95% CI 4.09–7.58, Z = 10.90, p=0.001), chronic pelvic inflammatory disease (OR = 4.70, 95% CI 4.07–5.42, Z = 21.21, p=0.001) and endometritis (OR = 5.09, 95% CI 4.03–6.43; Z = 13.63, p=0.001) in both primary endpoints and secondary endpoints. There is also a trend that Fuke Qianjin tablet combined with conventional therapy has lower adverse reaction rates than conventional therapy alone. CONCLUSION: Fuke Qianjin tablet combined with conventional therapy showed better clinical efficacy in the treatment of acute pelvic inflammatory disease, chronic pelvic inflammatory disease, and endometritis. There were no obvious drug-related adverse reactions. Fuke Qianjin tablet presented advantages in shortening the remission time of clinical symptoms, reducing the concentration of serum inflammatory factors, improving endometrial thickness, menstruation, and reducing relapse rate.
format Online
Article
Text
id pubmed-7904366
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-79043662021-03-04 Systematic Review and Meta-Analysis of Randomized Controlled Trials of Fuke Qianjin Tablet Jie, Pan Kai-Ni, Zuo Xiao-Mei, Wang Meng-Pei, Zhang Zhi-Heng, Wang Hao-Xiang, Zhang Wen-Tao, Zhu Evid Based Complement Alternat Med Research Article PURPOSE: The aim of the research was to evaluate the efficacy and safety associated with Fuke Qianjin tablet combined with conventional therapy in the treatment of pelvic inflammatory diseases and associated complications (endometritis) using a meta-analysis approach. Patients and Methods. We searched 8 electronic databases up to December 31, 2019, including PubMed, the Cochrane Library, Embase, Web of Science, CNKI, WanFang, VIP, and SinoMed. Eligible studies were clinical trials of Fuke Qianjin tablet combined with conventional therapy used in the treatment of acute pelvic inflammatory disease, chronic pelvic inflammatory disease, and endometritis. The meta-analysis was performed using STATA15 software. RESULTS: A total of 125 RCTs (n = 14,494) were shortlisted for the meta-analysis, which included 23 trials for acute pelvic inflammatory disease, 69 trials for chronic pelvic inflammatory disease, and 33 trials for endometritis. The overall analysis illustrated Fuke Qianjin tablet combined with conventional therapy was significantly more efficacious than conventional therapy alone across all types of antibiotics treatment for acute pelvic inflammatory disease (OR = 5.57, 95% CI 4.09–7.58, Z = 10.90, p=0.001), chronic pelvic inflammatory disease (OR = 4.70, 95% CI 4.07–5.42, Z = 21.21, p=0.001) and endometritis (OR = 5.09, 95% CI 4.03–6.43; Z = 13.63, p=0.001) in both primary endpoints and secondary endpoints. There is also a trend that Fuke Qianjin tablet combined with conventional therapy has lower adverse reaction rates than conventional therapy alone. CONCLUSION: Fuke Qianjin tablet combined with conventional therapy showed better clinical efficacy in the treatment of acute pelvic inflammatory disease, chronic pelvic inflammatory disease, and endometritis. There were no obvious drug-related adverse reactions. Fuke Qianjin tablet presented advantages in shortening the remission time of clinical symptoms, reducing the concentration of serum inflammatory factors, improving endometrial thickness, menstruation, and reducing relapse rate. Hindawi 2021-02-17 /pmc/articles/PMC7904366/ /pubmed/33680066 http://dx.doi.org/10.1155/2021/8861631 Text en Copyright © 2021 Pan Jie et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Jie, Pan
Kai-Ni, Zuo
Xiao-Mei, Wang
Meng-Pei, Zhang
Zhi-Heng, Wang
Hao-Xiang, Zhang
Wen-Tao, Zhu
Systematic Review and Meta-Analysis of Randomized Controlled Trials of Fuke Qianjin Tablet
title Systematic Review and Meta-Analysis of Randomized Controlled Trials of Fuke Qianjin Tablet
title_full Systematic Review and Meta-Analysis of Randomized Controlled Trials of Fuke Qianjin Tablet
title_fullStr Systematic Review and Meta-Analysis of Randomized Controlled Trials of Fuke Qianjin Tablet
title_full_unstemmed Systematic Review and Meta-Analysis of Randomized Controlled Trials of Fuke Qianjin Tablet
title_short Systematic Review and Meta-Analysis of Randomized Controlled Trials of Fuke Qianjin Tablet
title_sort systematic review and meta-analysis of randomized controlled trials of fuke qianjin tablet
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904366/
https://www.ncbi.nlm.nih.gov/pubmed/33680066
http://dx.doi.org/10.1155/2021/8861631
work_keys_str_mv AT jiepan systematicreviewandmetaanalysisofrandomizedcontrolledtrialsoffukeqianjintablet
AT kainizuo systematicreviewandmetaanalysisofrandomizedcontrolledtrialsoffukeqianjintablet
AT xiaomeiwang systematicreviewandmetaanalysisofrandomizedcontrolledtrialsoffukeqianjintablet
AT mengpeizhang systematicreviewandmetaanalysisofrandomizedcontrolledtrialsoffukeqianjintablet
AT zhihengwang systematicreviewandmetaanalysisofrandomizedcontrolledtrialsoffukeqianjintablet
AT haoxiangzhang systematicreviewandmetaanalysisofrandomizedcontrolledtrialsoffukeqianjintablet
AT wentaozhu systematicreviewandmetaanalysisofrandomizedcontrolledtrialsoffukeqianjintablet